Global CINV Existing and Pipeline Drugs Market Research Report 2023

Publication ID:

PB502236441

Publication Date:

February 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
Highlights
The global CINV Existing and Pipeline Drugs market was valued at US$ 1518.2 million in 2022 and is anticipated to reach US$ 1954.9 million by 2029, witnessing a CAGR of 3.2% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for CINV Existing and Pipeline Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for CINV Existing and Pipeline Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of CINV Existing and Pipeline Drugs include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck and Tesaro, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CINV Existing and Pipeline Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CINV Existing and Pipeline Drugs.
The CINV Existing and Pipeline Drugs market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global CINV Existing and Pipeline Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CINV Existing and Pipeline Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
Segment by Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of CINV Existing and Pipeline Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 CINV Existing and Pipeline Drugs Market Overview
1.1 Product Overview and Scope of CINV Existing and Pipeline Drugs
1.2 CINV Existing and Pipeline Drugs Segment by Type
1.2.1 Global CINV Existing and Pipeline Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Aloxi
1.2.3 Zofran Generic
1.2.4 Kytril Generic
1.2.5 Emend
1.2.6 Akynzeo
1.2.7 SUSTOL
1.2.8 Rolapitant
1.3 CINV Existing and Pipeline Drugs Segment by Application
1.3.1 Global CINV Existing and Pipeline Drugs Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Diagnostic Centers Therapeutics
1.3.5 Hospital Pharmacies
1.3.6 Drugstores
1.4 Global CINV Existing and Pipeline Drugs Market Size Estimates and Forecasts
1.4.1 Global CINV Existing and Pipeline Drugs Revenue 2018-2029
1.4.2 Global CINV Existing and Pipeline Drugs Sales 2018-2029
1.4.3 Global CINV Existing and Pipeline Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 CINV Existing and Pipeline Drugs Market Competition by Manufacturers
2.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global CINV Existing and Pipeline Drugs Average Price by Manufacturers (2018-2023)
2.4 Global CINV Existing and Pipeline Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Product Type & Application
2.7 CINV Existing and Pipeline Drugs Market Competitive Situation and Trends
2.7.1 CINV Existing and Pipeline Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest CINV Existing and Pipeline Drugs Players Market Share by Revenue
2.7.3 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 CINV Existing and Pipeline Drugs Retrospective Market Scenario by Region
3.1 Global CINV Existing and Pipeline Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global CINV Existing and Pipeline Drugs Global CINV Existing and Pipeline Drugs Sales by Region: 2018-2029
3.2.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2018-2023
3.2.2 Global CINV Existing and Pipeline Drugs Sales by Region: 2024-2029
3.3 Global CINV Existing and Pipeline Drugs Global CINV Existing and Pipeline Drugs Revenue by Region: 2018-2029
3.3.1 Global CINV Existing and Pipeline Drugs Revenue by Region: 2018-2023
3.3.2 Global CINV Existing and Pipeline Drugs Revenue by Region: 2024-2029
3.4 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.4.1 North America CINV Existing and Pipeline Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
3.4.3 North America CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.5.1 Europe CINV Existing and Pipeline Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
3.5.3 Europe CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific CINV Existing and Pipeline Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.7.1 Latin America CINV Existing and Pipeline Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
3.7.3 Latin America CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global CINV Existing and Pipeline Drugs Sales by Type (2018-2029)
4.1.1 Global CINV Existing and Pipeline Drugs Sales by Type (2018-2023)
4.1.2 Global CINV Existing and Pipeline Drugs Sales by Type (2024-2029)
4.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2018-2029)
4.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2018-2029)
4.2.1 Global CINV Existing and Pipeline Drugs Revenue by Type (2018-2023)
4.2.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2024-2029)
4.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2029)
4.3 Global CINV Existing and Pipeline Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global CINV Existing and Pipeline Drugs Sales by Application (2018-2029)
5.1.1 Global CINV Existing and Pipeline Drugs Sales by Application (2018-2023)
5.1.2 Global CINV Existing and Pipeline Drugs Sales by Application (2024-2029)
5.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2018-2029)
5.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2018-2029)
5.2.1 Global CINV Existing and Pipeline Drugs Revenue by Application (2018-2023)
5.2.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2024-2029)
5.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2029)
5.3 Global CINV Existing and Pipeline Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Helsinn
6.2.1 Helsinn Corporation Information
6.2.2 Helsinn Description and Business Overview
6.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Helsinn CINV Existing and Pipeline Drugs Product Portfolio
6.2.5 Helsinn Recent Developments/Updates
6.3 Heron Therapeutics
6.3.1 Heron Therapeutics Corporation Information
6.3.2 Heron Therapeutics Description and Business Overview
6.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio
6.3.5 Heron Therapeutics Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck CINV Existing and Pipeline Drugs Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Tesaro
6.5.1 Tesaro Corporation Information
6.5.2 Tesaro Description and Business Overview
6.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Tesaro CINV Existing and Pipeline Drugs Product Portfolio
6.5.5 Tesaro Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CINV Existing and Pipeline Drugs Industry Chain Analysis
7.2 CINV Existing and Pipeline Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CINV Existing and Pipeline Drugs Production Mode & Process
7.4 CINV Existing and Pipeline Drugs Sales and Marketing
7.4.1 CINV Existing and Pipeline Drugs Sales Channels
7.4.2 CINV Existing and Pipeline Drugs Distributors
7.5 CINV Existing and Pipeline Drugs Customers
8 CINV Existing and Pipeline Drugs Market Dynamics
8.1 CINV Existing and Pipeline Drugs Industry Trends
8.2 CINV Existing and Pipeline Drugs Market Drivers
8.3 CINV Existing and Pipeline Drugs Market Challenges
8.4 CINV Existing and Pipeline Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂